Veradermics, Inc
VeraDermics (NYSE: MANE) is a clinical-stage biopharmaceutical company developing treatments for prevalent aesthetic and dermatological conditions, with its current focus on pattern hair loss (PHL) in men and women. Its lead candidate, VDPHL01, is an extended-release oral formulation of minoxidil being evaluated in… From the company’s description.
In fiscal 2025, Veradermics, Inc reported a net loss of $70.00M. Operations used $71.60M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What Veradermics, Inc does
In the company’s own words
VeraDermics (NYSE: MANE) is a clinical-stage biopharmaceutical company developing treatments for prevalent aesthetic and dermatological conditions, with its current focus on pattern hair loss (PHL) in men and women. Its lead candidate, VDPHL01, is an extended-release oral formulation of minoxidil being evaluated in clinical trials as a potential non-hormonal PHL treatment. The registration-directed program includes two trials in men and one in women; the company is also conducting an exploratory Phase 2 trial. VeraDermics has no products approved for commercial sale and is preparing for potential commercialization through a planned dermatology-focused sales force and patient outreach. It aims to develop a focused portfolio of therapies for high-prevalence dermatologic conditions and may pursue additional internally developed or in-licensed candidates. The company retains exclusive worldwide rights to VDPHL01. VeraDermics reported no fiscal-year revenue or operating scale metrics in the provided business information. Its website is https://www.veradermics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW HAVEN, CT
- Fiscal year end
- December
- CIK
- 1827635
- SIC
- 2834
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Veradermics, Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Veradermics, Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Veradermics, Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Veradermics, Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Veradermics, Inc's last four quarterly filings that the numbers alone won't show?”